Automate Your Wheel Strategy on MTVA
With Tiblio's Option Bot, you can configure your own wheel strategy including MTVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MTVA
- Rev/Share 0.0
- Book/Share 2.8523
- PB 3.3727
- Debt/Equity 0.0125
- CurrentRatio 1.7365
- ROIC -2.6906
- MktCap 21177930.0
- FreeCF/Share -9.616
- PFCF -0.9922
- PE -1.3168
- Debt/Assets 0.0054
- DivYield 0
- ROE -2.2948
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MTVA | H.C. Wainwright | -- | Buy | -- | $12 | Sept. 4, 2025 |
| Initiation | MTVA | H.C. Wainwright | -- | Buy | -- | $12 | Dec. 30, 2024 |
News
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market.
Read More
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds of approximately $10.0 million, before deducting the placement agent's fees and other offering expenses payable by the company.
Read More
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Liver Fat Content Improvement in Systemic Inflammatory and Fibrosis Biomarkers Supports Beneficial Effects on Liver Health CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects.
Read More
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks Additional Cohorts Being Added to Determine Maximum Tolerated Dose CAMBRIDGE, Mass. , April 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic …
Read More
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect $16.0 Million in Cash at End of Fourth Quarter E xpected to Fund the Company Into the Third Quarter of 2025 CAMBRIDGE, Mass. , March 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, …
Read More
About MetaVia Inc. (MTVA)
- IPO Date 2016-08-05
- Website https://www.metaviatx.com
- Industry Biotechnology
- CEO Heon Kim Hyung
- Employees 9